Neural-tube defects with dolutegravir treatment from the time of conception

New England Journal of Medicine

Volumn 379, Issue 10, 2018, Pages 979-981

  Zash, Rebecca ^a   Makhema, Joseph ^b   Shapiro, Roger L ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ANTIRETROVIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTEGRASE INHIBITOR;

ADVERSE OUTCOME; ANENCEPHALUS; ANTIRETROVIRAL THERAPY; BOTSWANA; CONCEPTION; CONGENITAL DISORDER; CRYPTORCHISM; DRUG SURVEILLANCE PROGRAM; ENCEPHALOCELE; GESTATIONAL AGE; HIGH RISK PREGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INIENCEPHALY; LETTER; LIMB DEFECT; MENINGOCELE; MENINGOMYELOCELE; MOTHER; NEURAL TUBE DEFECT; PREGNANCY OUTCOME; PREVALENCE; PRIORITY JOURNAL; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; FEMALE; PREGNANCY; PREGNANCY COMPLICATION;

ANTI-RETROVIRAL AGENTS; BOTSWANA; DRUG THERAPY, COMBINATION; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; NEURAL TUBE DEFECTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE;

EID: 85053199994     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1807653     Document Type: Letter

References (2)

1. Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health 2018; 6(7): e804-e810.
2. Agrestri A, Coull BA. Approximate is better than "exact" for interval estimation of binomial proportions. Am Stat 1998; 52: 119-26.